Washington: Italian researchers have found an important molecular mechanism responsible for low back pain and other acute vertebral problems like cervical axial pain, all due to aging and degeneration of the vertebral column.
The team at the Catholic University of Sacred Heart in Rome, led by Dr. Luigi Aurelio Nasto and Enrico Pola, have also developed an experimental drug to inhibit this degenerative mechanism, by blocking its principal culprit, the molecule, “NF-kB” and tested it successfully in mice.
The study was carried out in collaboration with the University of Pittsburgh research team led by Paul Robbins, James Kang and Nam Vo.
Nasto and Pola found that high concentration of NF-kB causes the degeneration of intervertebral discs (the structures that separate and damp the vertebrae), a degenerative process that could affect also young adults (30 year old), especially if they adopt a sedentary lifestyle. In other words when NF-kB becomes overactive, it triggers a series of deleterious reactions that ultimately affect the physiological structure of the vertebral column.
Due to aging, obesity and sedentary lifestyle, intervertebral discs degenerate, leading to the progressive stiffening of the column. The intervertebral disc degeneration is responsible for syndromes such as chronic low back pain or neck pain that affects a large proportion of the adult population.
Back pain and neck pain are ranked among the leading causes of lost working hours and disability in adults Italian scientists found the mechanism behind the degenerative processes of the column.
They studied mice that are genetically programmed to age rapidly (progeroid mice). The average lifespan of normal mice is 2 years. The progeroid mice age more quickly and have a lifespan of 8 months. The progeroid mice perfectly mimic the process of spine degeneration that occur in old people and young adults who suffer from low back pain.
The researchers found that NF-kB plays a role in the degeneration of the spine. NF-kB is a transcription factor, it modulates the activation of specific target genes.
Researchers found that NF-kB activates many genes related to inflammation and turn off anti-inflammatory protective genes. Moreover in many studies NF-kB was found hyperactive in both the spines of old mice and old people.
The results of the Italian research suggested that NF-kB induces the onset of deleterious inflammatory processes and inhibit anti-inflammatory mechanisms.
Moreover “our study shows that by inhibiting NF-kB, we can stop spine degeneration,” said Dr. Nasto.
“Drugs that turn off or even only partially inactivate NF-kB could be used to prevent the degeneration of intervertebral discs in patients.
“In our study, we developed a specific drug, called NBD peptide, able to specifically inhibit the deleterious action of NF-kB – dr Pola explains. NBD has been already successfully tested by a US team in Pittsburgh to slow the course of muscular dystrophy in an animal model (NF-kB is also involved in this disease). This peptide will be soon tested in a clinical trial (phase I) to study its therapeutic effects on Duchenne muscular dystrophy,” Dr. Nasto added.
According to Nasto and Pola, NBD may also be used to counteract the aging of the vertebral column.
“We hope to develop other selective inhibitors of NF-kB to slow the degeneration of intervertebral discs” and cure low back pain, Pola concluded.
The findings were reported in the February 16 online edition of the journal Spine.